executive officer of Gilead Sciences, Inc., has been elected to its
board of directors. Gen-Probe's board now has eight members,
including seven who are not Gen-Probe employees.
-- Update on PROCLEIX ULTRIO Post-Marketing Study. To date,
participating blood banks have screened approximately 260,000 blood
donations in the post-marketing study for the PROCLEIX ULTRIO assay,
which is designed to demonstrate hepatitis B virus (HBV) "yield."
Yield is defined as HBV-infected blood donations that were intercepted
by the PROCLEIX ULTRIO assay, but that were initially negative based
on traditional serology tests. Gen-Probe believes that the first of
two required yield cases has been identified in the study, although
this must be confirmed through a regulatory submission to the FDA.
The FDA has approved the PROCLEIX ULTRIO assay to screen donated blood
for HIV-1 and hepatitis C virus (HCV), but not to screen for HBV, as
the initial clinical studies were not designed to, and did not,
demonstrate HBV yield. Gen-Probe and Novartis are conducting the
post-marketing study to demonstrate HBV yield and gain the associated
donor screening claim.
Webcast Conference Call
A live webcast of Gen-Probe's third quarter 2007 conference call for investors can be accessed at http://www.gen-probe.com beginning at 4:30 p.m. Eastern Time today. The webcast will be archived for at least 90 days. A telephone replay of the call also will be available for approximately 24 hours. The replay number is (800) 947-6450 for domestic callers and (203) 369-3539 for international callers.
Gen-Probe Incorporated is a global leader in the development,
manufacture and marketing of rapid, accurate and cost-effective nucleic
|SOURCE Gen-Probe Incorporated|
Copyright©2007 PR Newswire.
All rights reserved